Ovarian cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 6
• KRAS 6
• EGFR 3
• PTEN 2
• CTNNB1 0
• FAK 1
• MAPK 0
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Germany· EU contribution €202,125· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, France· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Italy· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Austria· EU contribution €3,977,586· until Sept 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, United Kingdom· EU contribution €7,998,791· until May 2029· 3 countries

5 of 23 running projects, newest first. Listed amounts together: €54.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Breast Cancer BRCA1 Carriers: a Pilot Study

  NCT05062174· Indiana University· Updated 15 Dec 2022

  “PI decision to cancel research”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

  NCT06169124· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 13
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 26

• Deep Learning of Position-Aligned Dynamic Cell Deformation Trajectories for Ovarian Cell Phenotyping in Hyperbolic Microchannels.

  Anal Chem, Oct 2026

• HRDPath: an explainable multi-model deep learning architecture for predicting homologous recombination deficiency from histopathology images.

  Nat Commun, Oct 2026

• iDCF: Interpretable deconvolution of cell fractions via biologically-informed deep learning using scRNA-seq data.

  PLoS Comput Biol, Aug 2026

• Deep learning radiomics nomogram based on enhanced CT for differentiating epithelial ovarian borderline tumors and early-stage epithelial ovarian cancers.

  BMC Cancer, Aug 2026

• STL-DeepBDC: A Robust Few-Shot Learning Framework for Multiclass Ovarian Tumor Classification in Ultrasound Outperforms Conventional Transfer Learning.

  Cancer Med, Aug 2026

• [Medical prior-guided TabMap deep learning model for ovarian cancer prediction and interpretability analysis].

  Nan Fang Yi Ke Da Xue Xue Bao, Jul 2026

• Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature.

  Adv Sci (Weinh), Jul 2026

• Real-time intraoperative identification of malignant ovarian tumors using deep learning of clinical gross specimen images.

  Taiwan J Obstet Gynecol, Jul 2026

• Temporal deep learning for 28-day mortality prediction in critically ill ovarian cancer patients: a multicenter development and validation study using hourly vital signs.

  J Ovarian Res, Jun 2026

• Deep learning of pretreatment ascites cytopathology for platinum-resistance risk stratification in advanced epithelial ovarian cancer.

  Neoplasia, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.